Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
Hematological Oncology · 2025
DOI: 10.1002/hon.70061 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Hematological Oncology, 2025. Verfasst von Lucio N Gordan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Florida Cancer Specialists & Research Institute, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Scientific Affairs LLC.
Abstract (Originalsprache)
Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are guideline‐recommended preferred regimens for initial treatment of transplant‐ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). This study aimed to systematically identify evidence on the clinical effectiveness of DRd and VRd as first‐line treatments for patients with TIE NDMM and to conduct a meta‐analysis. Ovid MEDLINE, Embase, and Cochrane Library were searched from January 2019 to June 2023, along with key congresses from January 2018 to June 2023. Bibliographies of relevant systematic literature reviews (SLR) were hand‐searched. Randomized controlled trials and appropriately adjusted non‐randomized studies comparing DRd versus VRd as first‐line treatment for TIE NDMM were included. Overall, five records from three unique studies were identified. The fixed‐effects meta‐analysis showed a lower risk of disease progression or death with DRd versus VRd using the naïve approach (hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.46, 0.77) as well as with the adjusted approach, which accounted for both double counting (i.e., two studies shared one comparison) and variance inflation due to studies with moderate and high risk of bias (HR: 0.56; 95% CI: 0.39, 0.82). In the absence of clinical trials with head‐to‐head comparison of these treatment regimens, these results could help inform the selection of optimal first‐line treatment for TIE NDMM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Florida Cancer Specialists & Research Institute, Gainesville, Florida, USA.
- Real World Value and Evidence Oncology, Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA.
- Real World Analytics, Janssen Scientific Affairs LLC, Titusville, New Jersey, USA.
- Georgetown University Medical Center, Washington, District of Columbia, USA.
- Value & Evidence Division, Marketing and Market Access, EVERSANA, Burlington, Canada.
ORCID-Profile: Rohan Medhekar, Bao-Ngoc Nguyen
Förderung
- Janssen Scientific Affairs LLC
Zitieren
APA
Gordan, L. N., Medhekar, R., Fu, A. Z., Shokoohi, M., Oliva Ramirez, A., Bonar, N., Nguyen, B. N., Spence, M., McTavish, R., Disher, T., Gautam, S., Gupta-Werner, N., Kaila, S., & Patel, A. J. (2025). Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis. Hematological Oncology. https://doi.org/10.1002/hon.70061
Vancouver
Gordan LN, Medhekar R, Fu AZ, Shokoohi M, Oliva Ramirez A, Bonar N, et al. Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis. Hematological Oncology. 2025. doi:10.1002/hon.70061
BibTeX
@article{Gordan2025,
author = {Gordan, Lucio N and Medhekar, Rohan and Fu, Alex Z and Shokoohi, Mostafa and Oliva Ramirez, Abril and Bonar, Nicolle and Nguyen, Bao-Ngoc and Spence, Michaela and McTavish, Rebecca and Disher, Tim and Gautam, Santosh and Gupta-Werner, Niodita and Kaila, Shuchita and Patel, Anjan J},
title = {Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70061}
}
EUVIMED